Case Study: Scale siRNA Manufacturing via Ligation with Bachem

As siRNA therapeutics expand into larger patient populations and commercial-scale indications, manufacturers face increasing pressure to deliver high-quality drug substance at greater scale, improve efficiency, and with improved sustainability. This case study highlights how our collaboration with Bachem advanced RNA manufacturing through a modular, enzymatic approach that combines short-fragment synthesis with engineered ligases to overcome the limitations of traditional oligonucleotide manufacturing.

Using vutrisiran as a model siRNA, the study demonstrates how optimized fragment and enzyme design via our FragLink can drive high ligation efficiencies, reduce purification burden, and enable scalable multi-kilogram GMP production. The result is a flexible manufacturing strategy that helps developers accelerate scale-up, improve manufacturing economics, and prepare for future commercial demand.